Bellerophon plunges as lung disease treatment fails in late-stage study

Bellerophon Therapeutics

05/06/2023 15:18

(Updates)
    ** Drug developer Bellerophon Therapeutics Inc's  BLPH.O 
shares plummet 82.9% to $1.20, hit 4-month low
    ** Company says its drug delivery system INOpulse did not
meet the main goal in a late-stage study for patients with a
type of lung disease
    ** Bellerophon says it does not see a path forward for
continuing the trial
    ** The main goal of the study was related to the change in
moderate to vigorous physical activity as measured by
actigraphy, a method of monitoring human rest/activity cycles,
after 16 weeks of chronic treatment
   ** Including session's fall, company's shares up 34.4% YTD

 (Reporting by Sriparna Roy and Pratik Jain in Bengaluru)
 ((Sriparna.Roy@thomsonreuters.com))